Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office ...
KXAN

HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration

- Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation Geneva, Switzerland, March 27, 2023 – HpVac SA, a company developing novel preventive and ...